Yangzijiang will take over 1.5 billion varieties of GSK 60% of the market danger.

Pharmaceutical Network August 7th, Yangzijiang Shanghai Heini Pharmaceuticals to copy 4 types of reported fumaatinnosivir dipyrifias tablets into the administrative approval stage.
-meter-net data show that in 2019 China's public medical institutions Fumaati Novovir difuran chip sales of more than 1.5 billion yuan, GlaxoSmithKline accounted for 69% of the market share.
Figure 1: Yangzijiang Fumaacid nofovir ivovir itunosillas registration progress Fumaatic dinofovir difurane the main active ingredient is noofovir bisphosphonates, can be directly competitively combined with natural DNA and inhibit viral polymerase, interfere with the replication of hepatitis B virus, so as to achieve therapeutic effect.
the product has significantly better than traditional antiviral advantages and low resistance, is the WHO guidelines recommended application of anti-HBV drugs.
Minet data show that in 2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal fumaatinovir itofuride tablet sales of more than 1.5 billion yuan, GlaxoSmithKline accounted for 69% of the market share, Chengdu Phetot with 17.18% of the market share followed.
Fumaatic difovir eire tablets for 4 plus 7 and the Alliance collection varieties, 4 plus 7 sets of mining, Chengdu Bent successfully won the bid, the winning bid is 0.6 yuan / piece;
Figure 2: Fumaatic nofovir film evaluation situation Minet net data show that there are currently 10 enterprises fumaatinovir dipifuran tablets through or as if passed through the consistency evaluation.
Qilu, Bete, Anhui Baker 3 enterprises submitted a supplementary application for consistency evaluation, after approval through consistency evaluation;
source: Minnet database, The State Drug Administration Note: data statistics as of August 6, if there are omissions, welcome to point!